Metavia INC 8-K filings

MetaVia Inc. announced that all patients in Part 3 of its Phase 1 obesity trial for DA-1726 have completed dose titration, with topline data expected in Q4 2026.

Metavia Inc. has filed a prospectus supplement for an at-the-market offering of up to $4 million in common stock, with legal counsel providing an opinion on the validity of the shares.

MetaVia Inc. announced that its stockholders approved an amendment to its 2022 Equity Incentive Plan, increasing the share reserve by 200,000 shares, and also approved a reverse stock split proposal.

MetaVia Inc. announced new late-breaking data for its obesity and metabolic disease portfolio, including positive Phase 1 results for DA-1726 and preclinical combination data for vanoglipel.

MetaVia Inc. announced new Phase 1 data for its dual agonist DA-1726 at EASL 2026, showing significant weight reduction and early liver improvements.

MetaVia Inc. announced that three late-breaking abstracts for its cardiometabolic assets, DA-1726 and vanoglipel, have been accepted for poster presentations at the American Diabetes Association's 2026 Scientific Sessions.

MetaVia Inc. announced that data on its novel dual agonist DA-1726 for obesity treatment will be presented at the EASL Congress 2026.

MetaVia Inc. has dosed the first patient in Part 3 of its Phase 1 clinical trial for DA-1726, a dual GLP-1/glucagon agonist for obesity, evaluating higher dose titration strategies.

MetaVia Inc. announced its 2025 financial results and a corporate update, highlighting positive Phase 1 data for DA-1726 and Phase 2a data for vanoglipel, alongside a reduced net loss and extended cash runway.

MetaVia Inc. has announced the discretionary cash bonuses for its Named Executive Officers for the fiscal year ended December 31, 2025.

MetaVia Inc. successfully closed a public offering, raising $9.3 million to fund clinical development for its cardiometabolic disease treatments.

MetaVia Inc. announced preliminary unaudited financial results for 2025, reporting approximately $10.3 million in cash and no outstanding debt.

MetaVia Inc. announced positive statistically significant results from its Phase 1 clinical trial of DA-1726 for obesity, demonstrating robust weight loss, glycemic response, and hepatic benefits.

MetaVia Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the previously reported listing matter.

MetaVia Inc. will implement a 1-for-11 reverse stock split effective December 4, 2025, to meet Nasdaq's continued listing requirements.

MetaVia Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, pushing the deadline to May 26, 2026.

MetaVia Inc. announced positive Phase 2a clinical trial data for vanoglipel (DA-1241) in treating metabolic dysfunction-associated steatohepatitis (MASH), demonstrating improvements in glucose control, liver health, and lipid profiles.

MetaVia Inc. announced positive Phase 1 results for its obesity drug DA-1726 and met the primary endpoint in its Phase 2a trial for MASH treatment Vanoglipel, highlighting significant progress in its cardiometabolic pipeline.

MetaVia Inc. announced its third quarter 2025 financial results and provided a corporate update highlighting strong progress in its cardiometabolic disease pipeline, including promising Phase 1 data for its obesity drug DA-1726 and Phase 2a results for its MASH treatment vanoglipel.

MetaVia Inc. released an updated corporate presentation highlighting positive Phase 1 data for its obesity drug DA-1726 and Phase 2a top-line results for its MASH treatment DA-1241.

MetaVia Inc. announced positive Q2 2025 financial results and significant clinical progress for its cardiometabolic drug candidates, extending its cash runway into 2026.

MetaVia Inc. announced an extension of its DA-1726 Phase 1 clinical trial for obesity to 8 weeks, aiming for more robust efficacy and safety data.

MetaVia Inc. announced a research collaboration with Syntekabio, Inc. to leverage AI for expanding the therapeutic potential of its novel oral GPR119 agonist, DA-1241, following positive Phase 2a results.

MetaVia Inc. announced the dosing of the first patient in the 48 mg multiple ascending dose cohort of its Phase 1 clinical trial for DA-1726, a dual GLP1R and GCGR agonist for obesity, with top-line data expected in the fourth quarter of 2025.

MetaVia Inc. stockholders approved all six proposals at its annual meeting, including a reverse stock split, the election of two Class III directors, and the issuance of shares related to pre-funded warrants.

MetaVia Inc. has been notified by Nasdaq of non-compliance with the minimum bid price requirement, initiating a 180-day period to regain compliance or face potential delisting.

MetaVia Inc. releases updated corporate presentation highlighting positive Phase 1 results for DA-1726, a novel GLP1R/GCGR dual agonist for obesity, and Phase 2a top-line data for DA-1241 in MASH.

MetaVia reports positive Phase 1 trial results for DA-1726, showing compelling weight loss and glucose control, and secures $10 million in a private placement to fund operations into 2026.

MetaVia Inc. announces a $10 million private placement to fund working capital and clinical development of DA-1726 for obesity treatment.

MetaVia Inc. announces positive Phase 2a clinical trial results for DA-1241, demonstrating hepatoprotective and glucose-regulating effects in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH).